Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Determining the minimum clinically important differences for outcomes in the DOMINO trial.
Howard R, Phillips P, Johnson T, O'Brien J, Sheehan B, Lindesay J, Bentham P, Burns A, Ballard C, Holmes C, McKeith I, Barber R, Dening T, Ritchie C, Jones R, Baldwin A, Passmore P, Findlay D, Hughes A, Macharouthu A, Banerjee S, Jones R, Knapp M, Brown RG, Jacoby R, Adams J, Griffin M, Gray R. Howard R, et al. Among authors: passmore p. Int J Geriatr Psychiatry. 2011 Aug;26(8):812-7. doi: 10.1002/gps.2607. Epub 2010 Sep 16. Int J Geriatr Psychiatry. 2011. PMID: 20848576
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT.
Jones R, Sheehan B, Phillips P, Juszczak E, Adams J, Baldwin A, Ballard C, Banerjee S, Barber B, Bentham P, Brown R, Burns A, Dening T, Findlay D, Gray R, Griffin M, Holmes C, Hughes A, Jacoby R, Johnson T, Jones R, Knapp M, Lindesay J, McKeith I, McShane R, Macharouthu A, O'Brien J, Onions C, Passmore P, Raftery J, Ritchie C, Howard R; DOMINO-AD team. Jones R, et al. Among authors: passmore p. Trials. 2009 Jul 24;10:57. doi: 10.1186/1745-6215-10-57. Trials. 2009. PMID: 19630974 Free PMC article. Clinical Trial.
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P. Howard R, et al. Among authors: passmore p. N Engl J Med. 2012 Mar 8;366(10):893-903. doi: 10.1056/NEJMoa1106668. N Engl J Med. 2012. PMID: 22397651 Free article. Clinical Trial.
Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations.
Webster L, Groskreutz D, Grinbergs-Saull A, Howard R, O'Brien JT, Mountain G, Banerjee S, Woods B, Perneczky R, Lafortune L, Roberts C, McCleery J, Pickett J, Bunn F, Challis D, Charlesworth G, Featherstone K, Fox C, Goodman C, Jones R, Lamb S, Moniz-Cook E, Schneider J, Shepperd S, Surr C, Thompson-Coon J, Ballard C, Brayne C, Burke O, Burns A, Clare L, Garrard P, Kehoe P, Passmore P, Holmes C, Maidment I, Murtagh F, Robinson L, Livingston G. Webster L, et al. Among authors: passmore p. Health Technol Assess. 2017 May;21(26):1-192. doi: 10.3310/hta21260. Health Technol Assess. 2017. PMID: 28625273 Free PMC article.
A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocol.
Greenan C, Murphy L, Yu LM, Kehoe PG, Coulthard E, Bath P, Stewart R, Jones R, Corbett A, Thomas A, Connelly P, Arrojo F, Canning R, Wallach S, Henderson C, McGuinness B, O'Sullivan M, Holmes C, Knapp M, Ballard C, Passmore P; AFFECT Investigators. Greenan C, et al. Among authors: passmore p. Trials. 2016 Jul 18;17(1):324. doi: 10.1186/s13063-016-1449-3. Trials. 2016. PMID: 27430267 Free PMC article. Clinical Trial.
Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.
O'Brien JT, Holmes C, Jones M, Jones R, Livingston G, McKeith I, Mittler P, Passmore P, Ritchie C, Robinson L, Sampson EL, Taylor JP, Thomas A, Burns A. O'Brien JT, et al. Among authors: passmore p. J Psychopharmacol. 2017 Feb;31(2):147-168. doi: 10.1177/0269881116680924. Epub 2017 Jan 20. J Psychopharmacol. 2017. PMID: 28103749 Review.
Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations.
Webster L, Groskreutz D, Grinbergs-Saull A, Howard R, O'Brien JT, Mountain G, Banerjee S, Woods B, Perneczky R, Lafortune L, Roberts C, McCleery J, Pickett J, Bunn F, Challis D, Charlesworth G, Featherstone K, Fox C, Goodman C, Jones R, Lamb S, Moniz-Cook E, Schneider J, Shepperd S, Surr C, Thompson-Coon J, Ballard C, Brayne C, Burns A, Clare L, Garrard P, Kehoe P, Passmore P, Holmes C, Maidment I, Robinson L, Livingston G. Webster L, et al. Among authors: passmore p. PLoS One. 2017 Jun 29;12(6):e0179521. doi: 10.1371/journal.pone.0179521. eCollection 2017. PLoS One. 2017. PMID: 28662127 Free PMC article. Review.
AD2000: design and conclusions.
Holmes C, Burns A, Passmore P, Forsyth D, Wilkinson D. Holmes C, et al. Among authors: passmore p. Lancet. 2004 Oct 2-8;364(9441):1213-4; author reply 1216-7. doi: 10.1016/S0140-6736(04)17127-4. Lancet. 2004. PMID: 15464172 No abstract available.
155 results